AMARIN CORP PLC\UK Estimated Litigation Liability
AMARIN CORP PLC\UK (AMRN) had Estimated Litigation Liability of $6.30 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LitigationReserve · last filed 2026-07-29
- 2026-06-30: Estimated Litigation Liability $6.30M.
| Period end | Estimated Litigation Liability |
|---|---|
| 2026-06-30 | $6.30M 10-Q · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |